前往研报中心>>
HARMONi-3 remains the decisive catalyst
内容摘要
The FDA declined approval of ivonescimab plus chemotherapy for 2L EGFR-mutant NSCLC, concluding that PFS improvement without statistically significant overall survival did not establish a positive benefit-risk profile. The underlying global HARMONi trial achieved significant PFS improvement, but its primary OS analysis missed significance (HR 0.79, p=0.057); longer follow-up subsequently showed an OS HR of 0.76 across the overall, Asian and Western populations, but this was post-hoc and insufficient to change the FDA’s assessment. Nevertheless, 2L EGFR-mutant NSCLC remains a relatively small indication, representing less than 5% of our global peak sales estimate for ivonescimab. Moreover, the limitations of HARMONi are not directly transferable to Summit’s broader development programme. HARMONi combined Chinese and Western patients, with less mature Western follow-up at the primary analysis, whereas HARMONi-3 is a purpose-built, multiregional first-line study with separately powered squamous and non-squamous cohorts. We look forward to the upcoming HARMONi-3 readouts, and maintain our BUY rating on Akeso with a target price of HK$99.34.
HARMONi-3 is far more important in determining whether ivonescimab can outperform SoC in large indications. In KEYNOTE-407, the first-line SoC of Keytruda plus chemotherapy achieved a mPFS of 6.4 vs 4.8 months for chemotherapy alone (HR 0.56), and a mOS of 15.9 vs 11.3 months (HR 0.64). These results set the benchmark ivonescimab will need to surpass. Investor sentiment was shaken in April when a newly introduced interim analysis of the squamous cohort in HARMONi-3 failed to reach statistical significance for PFS, although the comparison was made against a stringent interim efficacy boundary. The trial remains blinded, and the number of PFS events required for the primary analysis in the squamous cohort is expected to be reached in 4Q26, with a planned early interim OS analysis conducted in conjunction with it; a separate interim OS analysis is planned for 1H27. For the nsq-cohort, the PFS event threshold is expected to be met in 1H27.
Competitive pressure is intensifying, but the broadening combination strategy preserves substantial optionality. In the PD-(L)1/VEGF space, Pfizer’s tivunatamig, BioNTech/BMS’s pumitamig, AbbVie’s ABBV-1480, and Merck’s MK-2010 are all advancing into global Ph3 development in first-line NSCLC, eroding ivonescimab’s first-mover advantage. Offsetting this, AstraZeneca’s US$2bn equity investment in Summit has provided significant capital to expand clinical development, with combination studies pairing ivonescimab with Datroway (TROP2 ADC) in lung and breast cancers and with sonesitatug vedotin (LDN18.2 ADC) in gastrointestinal tumours in planning. Meanwhile, ivonescimab is increasingly emerging as a preferred backbone for combination strategies across both proprietary and partnered assets, including Akeso’s in-house HER3 ADC and TROP2/Nectin-4 ADC, GSK’s B7-H3 ADC, Pfizer’s Nectin-4 ADC, and Biokin’s EGFR/HER3 ADC. Beyond ADCs, ivonescimab is also being evaluated in combination with RAS(ON) inhibitors, as well as with CD47 mAb, HIF-2α inhibitors, and FGFR inhibitors.
Maintain BUY. The CRL delays US commercialization, while HARMONi-3 and successful combination trials remain central to the Akeso’s investment case. We revise our DCF-derived TP from HK$138.42 to HK$99.34 (WACC: 9.67%, terminal growth: 3.0%).
回复 0 条,有 0 人参与

我有话说

禁止发表不文明、攻击性、及法律禁止言语;

还可以输入 140 个字符  
以下网友评论只代表同花顺网友的个人观点,不代表同花顺金融服务网观点。